SecurityMSRT / MassRoots, Inc. (57630J106)
IndustryComputer Programming, Data Processing, And Other Computer Related Services
Common Shares Outstanding154,487,534 shares (as of 2018-03-31)
Total Insiders15
Total Directors8
Total Officers6

Stock Insider Trading (from SEC Form 4)

MassRoots, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

MSRT / MassRoots, Inc. insiders include PULLAR GEORGE R, Hunt Daniel Charles, Fortier Hyler, KYTE CECIL BOND, Dietrich Isaac, Keber Vincent, Kveton Scott C, SHELTON NATHAN E, Farrar Graham Osborn Steven Lee II, and BLUM CHARLES, Seeb Ean, GALEY LANCE, FITCH TERENCE ANTHONY, Quintero Jesus, .

Insider Roster

Insider Dir Off 10% Shares Owned
Quintero Jesus Chief Financial Officer
X 320,000
Kveton Scott C Chief Executive Officer
X 3,888,533
Osborn Steven Lee II
Farrar Graham Director
X 500,000
X 250,000
X 750,000
X 0
Keber Vincent Director
X 250,000
X 100,000
Seeb Ean Director
X 393,788
Dietrich Isaac Chief Executive Officer, Director, 10% Owner
X X X 17,783,831
PULLAR GEORGE R Chief Financial Officer
Hunt Daniel Charles Chief Operations Officer
GALEY LANCE Chief Technology Officer
Fortier Hyler 10% Owner

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Form Insider Code 10b-5 Direct Share
Post Value
2018-02-07 4 Quintero Jesus S D 0.45 -15,000 320,000 144,000
2018-03-09 4 Osborn Steven Lee II S D 0.26 -20,000 2,762,321 718,203
2018-03-09 4 Osborn Steven Lee II S D 0.251 -17,500 2,782,321 698,363
2018-03-08 4 Osborn Steven Lee II S D 0.25 -144,821 2,799,821 699,955
2018-03-08 4 Osborn Steven Lee II S D 0.251 -45,000 2,944,642 739,105
2018-03-09 4 Kveton Scott C S D 0.26 -20,000 3,888,533 1,011,019
2018-03-09 4 Kveton Scott C S D 0.251 -17,500 3,908,533 981,042
2018-03-08 4 Kveton Scott C S D 0.25 -144,821 3,926,033 981,508
2018-03-08 4 Kveton Scott C S D 0.2526 -45,000 4,070,854 1,028,298
2018-03-08 4 Kveton Scott C S D 0.2526 -5,000 4,115,854 1,039,665
2018-03-08 4 Kveton Scott C S D 0.252 -25,000 4,120,854 1,038,455
2018-02-01 4 KYTE CECIL BOND J D 750,000 750,000
2018-02-01 4 BLUM CHARLES J D 250,000 250,000
2017-12-12 4 Seeb Ean Denver Relief Consulting LLC J I -500,000 393,788
2017-12-12 4 FITCH TERENCE ANTHONY J D -750,000 100,000
2017-12-12 4 Keber Vincent J D -500,000 250,000
2017-09-06 4 Keber Vincent M D 394,858 1,144,858
2017-07-26 4 FITCH TERENCE ANTHONY A D 750,000 850,000
2017-07-26 4 Seeb Ean By Denver Reliev Consulting LLC A I 500,000 893,788
2017-07-26 4 Keber Vincent A D 500,000 750,000
2017-07-21 4 Dietrich Isaac P D 0.5 20,000 17,783,831 8,891,916
2017-01-01 4 PULLAR GEORGE R A D 100,000 100,000
2017-01-25 4 Seeb Ean By Denver Relief Consulting LLC J I 113,788 393,788
2017-01-27 4 Quintero Jesus S D 0.9922 -3,000 97,000 96,243
2016-12-30 4 Hunt Daniel Charles S D 1.0104 -65,000 255,000 257,652
2016-12-29 4 Hunt Daniel Charles S D 0.9957 -35,000 320,000 318,624
2016-09-30 4 Hunt Daniel Charles A D 25,000 355,000
2016-10-03 4 GALEY LANCE A D 600,000 600,000
2016-08-31 4 Dietrich Isaac P D 0.5 20,000 17,743,831 8,871,916
2016-01-05 4 Hunt Daniel Charles A D 100,000 330,000
2015-03-11 4 Seeb Ean By E-3 Events, LLC P I 0.5 30,000 280,000 140,000
Open market or private purchase of non-derivative or derivative security
Open market or private sale of non-derivative or derivative security
Grant, award, or other acquisition of securities from the company (such as an option)
Conversion of derivative
Sale or transfer of securities back to the company
Payment of exercise price or tax liability using portion of securities received from the company
Gift of securities by or to the insider
Equity swaps and similar hedging transactions
Exercise or conversion of derivative security received from the company (such as an option)
A transaction voluntarily reported on Form 4
Other (accompanied by a footnote describing the transaction)

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

MassRoots: Building A New Potemkin Business Under The Spectre Of An Old Dying One

2018-04-25 seekingalpha
The company's latest charade is focused around its Blockchain Technologies Inc. subsidiary, a business created around the peak of the cryptocurrency bubble.

MassRoots' (MSRT) CEO Isaac Dietrich presents Recent and Upcoming Business Developments Conference (Transcript)

2018-02-06 seekingalpha
MassRoots, Inc. (OTCQB:MSRT) Recent and Upcoming Business Developments Conference Call February 1, 2018 9:00 AM ET

MassRoots Fights For Its Cannabis Future At The 11th Hour

2017-12-13 seekingalpha
MSRT has fallen from a 2017 all-time-high of $1.13 to lows of $0.13. It has also fallen by 60% since my last article. (0-2)